医学
赛马鲁肽
胰高血糖素样肽1受体
2型糖尿病
肥胖
兴奋剂
2型糖尿病
糖尿病
内科学
内分泌学
受体
利拉鲁肽
作者
William Wang,Nora D. Volkow,Nathan A. Berger,Pamela B. Davis,David C. Kaelber,Rong Xu
摘要
Reports of reduced desire to smoke in patients treated with semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus (T2DM) and obesity, have raised interest about its potential benefit for tobacco use disorders (TUDs).
科研通智能强力驱动
Strongly Powered by AbleSci AI
爱静静
加菲丰丰
shinysparrow
寻道图强
可口可乐了
乐乐乐乐乐乐
景辣条
充电宝
精明元霜
mmyhn
sirius
AireenBeryl531
星辰大海
kento
morena
丘比特
浅尝离白
Singularity
从容芮
共享精神
皖公网安备34019202002308
